Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
We recently identified cardiomyocyte dysfunction in the early stage of type 2 diabetes (i.e., diet-induced insulin resistance). The present investigation was designed to determine whether a variety of clinically relevant interventions are sufficient to prevent and reverse cardiomyocyte dysfunction in sucrose (SU)-fed insulin-resistant rats. Subsets of animals were allowed to exercise (free access to wheel attached to cage) or were treated with bezafibrate in drinking water to determine whether these interventions would prevent the adverse effects of SU feeding on cardiomyocyte function. After 6-8 wk on diet and treatment, animals were surgically prepared to assess whole body insulin sensitivity (intravenous glucose tolerance test), and isolated ventricular myocyte mechanics were evaluated (video edge recording). SU feeding produced hyperinsulinemia and hypertriglyceridemia, with euglycemia, and induced characteristic whole body insulin resistance. Both exercise and bezafibrate treatment prevented these metabolic abnormalities. Ventricular myocyte shortening and relengthening were slower in SU-fed rats (42-63%) compared with starch (ST)-fed controls, and exercise or bezafibrate completely prevented cardiomyocyte dysfunction in SU-fed rats. In separate cohorts of animals, after 5 wk of SU feeding, animals were either switched back to an ST diet or given menhaden oil for an additional 7-9 wk to determine whether the cardiomyocyte dysfunction was reversible. Both interventions have previously been shown to have favorable metabolic effects, and both improved myocyte mechanics, but only the ST diet reversed all indications of cardiomyocyte dysfunction induced by SU feeding. Thus phenotypic changes in cardiomyocyte mechanics associated with early stages of type 2 diabetes were found to be both preventable and reversible with clinically relevant treatments, suggesting that the cellular processes contributing to this dysfunction are modifiable.
Davidoff
Amy J
AJ
Univ. of New England, College of Osteopathic Medicine, 11 Hills Beach Rd., Biddeford, ME 04005, USA. adavidoff@une.edu
Mason
Meredith M
MM
Davidson
Michael B
MB
Carmody
Marybeth W
MW
Hintz
Kadon K
KK
Wold
Loren E
LE
Podolin
Deborah A
DA
Ren
Jun
J
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000517:prevention & control*; D019422:Dietary Sucrose; D006331:Heart Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006946:Hyperinsulinism / Q000378:metabolism / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism*; D010805:Physical Conditioning, Animal; D005082:Physical Exertion; D051381:Rats; D017208:Rats, Wistar
D019422:Dietary Sucrose; D000960:Hypolipidemic Agents; D001629:Bezafibrate